Funding for this research was provided by:
Swedish Rheumatism Association (R-664091, R-664091, R-664091)
Lunds Universitet (ALFSKANE-446501)
Lund University
Article History
Received: 29 January 2024
Accepted: 20 March 2024
First Online: 10 April 2024
Declarations
:
: SE reports consulting for AbbVie, Amgen, Janssen-Cilag, Novartis, and UCB Pharma. CT reports honoraria for lectures from AbbVie, Boehringer-Ingelheim, Nordic Drugs, Novartis, Pfizer, and Roche. PZ and AS report no competing interests.
: The study was approved by the Swedish Ethical Review Authority (September 23, 2000; registration number 2020–04041, with amendment on February 16, 2021; registration number 2021–00717). As all delivered register data were pseudonymized, the investigators did not have access to personal identity information. The Ethical Review Authority decided that individual informed consent was not necessary for this study.
: Not applicable.